Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

Summary

The survey is a retrospective study to evaluate the prognotic value of EGFR expression, KRAS mutations and tumor sideness in patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or fourth-line setting.

Timeline

Start

2013-10-01

Primary completion

2018-06-01

Completion

2018-06-01

Drugs

Indications